First patient dosed in BioNTech Phase II trial of mRNA cancer vaccine
Dosing has commenced in BioNTech's BNT111 Phase II cancer vaccine trial in advanced melanoma.
ByOncology
OnQuality: developing treatments to combat cancer therapy side effects
OnQuality’s chief medical officer and co-founder Hong Tang discusses the firm’s pipeline of cancer supportive care drugs.
By
Exscientia to start world-first trials of AI-designed immuno-oncology drug
Oxford-based AI drug discovery firm Exscientia is preparing to begin Phase I clinical trials with the world’s first AI-designed molecule…
By
uniQure gene therapy found “highly unlikely” to be cause of liver cancer case
Netherlands-based gene therapy developer uniQure has announced the results of a comprehensive investigation into the case of hepatocellular carcinoma (HCC)…
By
Globalisation of US cancer trials is reducing enrolment of Black patients, study finds
The increasing globalisation of US-initiated cancer clinical trials is linked to lower enrolment of Black patients, a new study has…
By
Merck withdraws Keytruda from SCLC indication amid FDA crackdown
On 1 March, Merck announced the voluntary withdrawal of its Keytruda (pembrolizumab) immunotherapy for the treatment of patients with metastatic…
By
Sandoz Abandons US Development of Rixathon
Chloé Thépaut, MRes, Oncology Senior Analyst, GlobalData, examines the implications of Sandoz’s abandoned attempt to have Rixathon approved in the…
Industry Viewpoints: Patient Recruitment and Expanded Access
In the latest Industry Viewpoint, Howard Fingert speaks to CTA’s Elizabeth Williams about the challenges of patient recruitment